EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Surface‐Engineering of Pancreatic Islets with Chitosan Microparticles to Inhibit IBMIR in Islet Xenotransplantation

Manju Shrestha iD, Tiep Tien Nguyen, Junhyeung Park, Dinesh Chaudhary, Rabyya Kausar, Yu Seok Youn, Ji Hoon Jeong, Jung Heon Lee, Sei Won Lee, Hye Yun Park, Simmyung Yook, Jee-Heon Jeong iD

Small · 2025-09 · 21 (38)

DOI: 10.1002/smll.202503470 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Small, online erschienen am 07.08.2025. Verfasst von Manju Shrestha und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Precision Medicine, School of Medicine, Sungkyunkwan University, Suwon, Gyeonggi, 16419, Republic of Korea. Hauptthemen laut MEDLINE: Chitosan, Islets of Langerhans Transplantation, Islets of Langerhans, Transplantation, Heterologous. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Research Foundation of Korea, Korea Fund for Regenerative Medicine (KFRM), Korea Health Industry Development Institute (KHIDI).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Intraportal islet transplantation is an effective beta‐cell replacement therapy for restoring insulin production in patients with type 1 diabetes. However, transplanted islets are rapidly lost due to a strong immediate inflammatory reaction, termed as instant blood‐mediated inflammatory reaction (IBMIR). Current preventive therapies for IBMIR face systemic side effects such as bleeding risks. Although surface islet modification with biocompatible polymers or antithrombotic molecules shows promise, the limited anchoring of these molecules on the islet surface, caused by low conjugation efficiency and complex procedures in current methods, often lead to suboptimal outcomes. In this study, a novel islet conjugation platform is presented for effectively delivering heparin (HEP) for overcoming IBMIR. The islet surface is first conjugated with chitosan microparticles (CSMP) via electrostatic interaction. HEP is then absorbed into the conjugated CSMP with a high amount (4.4 ng IEQ −1 ). The conjugation system is stable and highly biocompatible with cell viability and functionality in vitro. Importantly, intraportal transplantation of the HEP/CSMP‐islets significantly reduces coagulation and complement activation and improves blood glucose levels, thereby achieving a higher survival rate. This strategy can provide a versatile platform to deliver various therapeutic agents, including bioactive anti‐inflammatory cytokines and growth factors, leading to enhanced islet transplantation outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ChitosanIslets of Langerhans TransplantationIslets of LangerhansTransplantation, HeterologousInflammationTissue EngineeringAnimalsHeparinHumansMice

Stichwörter der Autor:innen

chitosan microparticlesinstant blood‐mediated inflammatory reactionislet transplantationsurface‐engineeringtype 1 diabetes

Substanzen

ChitosanHeparin

Autor:innen und Institutionen

  • Department of Precision Medicine, School of Medicine, Sungkyunkwan University, Suwon, Gyeonggi, 16419, Republic of Korea.
  • School of Pharmacy, Sungkyunkwan University, Suwon, Gyeonggi, 16419, Republic of Korea.
  • School of Advanced Materials Science and Engineering, Sungkyunkwan University, Suwon, Gyeonggi, 16419, Republic of Korea.
  • Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 05505, Republic of Korea.
  • Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, 06351, Republic of Korea.
  • Department of Biopharmaceutical Convergence, Sungkyunkwan University, Suwon, Gyeonggi, 16419, Republic of Korea.

ORCID-Profile: Manju Shrestha, Jee-Heon Jeong

Förderung

  • National Research Foundation of Korea
  • Korea Fund for Regenerative Medicine (KFRM)
  • Korea Health Industry Development Institute (KHIDI)

Zitieren

APA

Shrestha, M., Nguyen, T. T., Park, J., Chaudhary, D., Kausar, R., Youn, Y. S., Jeong, J. H., Lee, J. H., Lee, S. W., Park, H. Y., Yook, S., & Jeong, J. H. (2025). Surface‐Engineering of Pancreatic Islets with Chitosan Microparticles to Inhibit IBMIR in Islet Xenotransplantation. Small, 21(38). https://doi.org/10.1002/smll.202503470

Vancouver

Shrestha M, Nguyen TT, Park J, Chaudhary D, Kausar R, Youn YS, et al. Surface‐Engineering of Pancreatic Islets with Chitosan Microparticles to Inhibit IBMIR in Islet Xenotransplantation. Small. 2025;21(38). doi:10.1002/smll.202503470

BibTeX
@article{Shrestha2025,
  author = {Shrestha, Manju and Nguyen, Tiep Tien and Park, Junhyeung and Chaudhary, Dinesh and Kausar, Rabyya and Youn, Yu Seok and Jeong, Ji Hoon and Lee, Jung Heon and Lee, Sei Won and Park, Hye Yun and Yook, Simmyung and Jeong, Jee-Heon},
  title = {Surface‐Engineering of Pancreatic Islets with Chitosan Microparticles to Inhibit IBMIR in Islet Xenotransplantation},
  journal = {Small},
  year = {2025},
  volume = {21},
  number = {38},
  doi = {10.1002/smll.202503470}
}
Kostenlos starten →